News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
10,208 Results
Type
Article (243)
Company Profile (1)
Press Release (9942)
Section
Business (6358)
Career Advice (4)
Deals (766)
Drug Delivery (3)
Drug Development (707)
FDA (96)
Job Trends (254)
News (7097)
Policy (221)
Tag
Academia (7)
ADA (3)
Allergies (1)
Alliances (129)
ALS (12)
Alzheimer's disease (31)
Antibody-drug conjugate (ADC) (12)
Approvals (118)
Artificial intelligence (1)
ASCO (10)
Autoimmune disease (2)
Best Places to Work (251)
Biosimilars (4)
Bladder cancer (3)
Brain cancer (2)
Breast cancer (15)
Cancer (129)
Cardiovascular disease (8)
Career advice (4)
CAR-T (2)
CDMO (1)
Cell therapy (6)
Cervical cancer (2)
Clinical research (742)
Collaboration (8)
Compensation (13)
COVID-19 (30)
CRISPR (1)
C-suite (2)
Cystic fibrosis (2)
Data (200)
Depression (3)
Dermatology (1)
Diabetes (11)
Diagnostics (181)
Digital health (2)
Drug discovery (3)
Drug pricing (2)
Drug shortages (1)
Earnings (7010)
Editorial (1)
Events (528)
Executive appointments (3)
FDA (221)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (10)
Gene editing (4)
Gene therapy (1)
GLP-1 (25)
Government (30)
Guidances (81)
Healthcare (300)
Hematology (4)
HIV (1)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (8)
Immuno-oncology (1)
Indications (3)
Infectious disease (33)
Intellectual property (5)
IPO (674)
Job creations (19)
Job search strategy (4)
Kidney cancer (1)
Labor market (1)
Layoffs (3)
Legal (20)
Liver cancer (1)
Lung cancer (23)
Lymphoma (20)
Manufacturing (8)
MASH (5)
Medical device (348)
Medtech (358)
Mergers & acquisitions (110)
Metabolic disorders (47)
mRNA (1)
Multiple sclerosis (1)
Neurodegenerative disease (3)
Neuropsychiatric disorders (3)
Neuroscience (55)
NextGen: Class of 2026 (72)
Non-profit (16)
Obesity (33)
Opinion (2)
Ovarian cancer (5)
Pain (6)
Pancreatic cancer (5)
Parkinson's disease (2)
Patents (4)
Patient recruitment (11)
People (126)
Pharmaceutical (1)
Phase 1 (150)
Phase 2 (288)
Phase 3 (365)
Pipeline (611)
Postmarket research (26)
Preclinical (40)
Press Release (1)
Prostate cancer (4)
Radiopharmaceuticals (8)
Rare diseases (17)
Real estate (13)
Regulatory (232)
Reports (2)
Research institute (12)
RSV (1)
Schizophrenia (1)
Series A (2)
Sickle cell disease (3)
Special edition (3)
Startups (7)
Tariffs (1)
Vaccines (11)
Venture capital (2)
Weight loss (23)
Women's health (3)
Date
Today (2)
Last 7 days (4)
Last 30 days (71)
Last 365 days (838)
2026 (605)
2025 (788)
2024 (873)
2023 (1001)
2022 (1150)
2021 (1073)
2020 (843)
2019 (623)
2018 (516)
2017 (339)
2016 (197)
2015 (332)
2014 (220)
2013 (97)
2012 (149)
2011 (176)
2010 (156)
Location
Africa (5)
Alabama (2)
Arizona (9)
Asia (574)
Australia (47)
California (394)
Canada (95)
China (37)
Colorado (16)
Connecticut (15)
Delaware (8)
Europe (1195)
Florida (34)
Georgia (11)
Illinois (32)
India (2)
Indiana (20)
Japan (19)
Kansas (5)
Kentucky (1)
Louisiana (3)
Maine (3)
Maryland (42)
Massachusetts (278)
Michigan (15)
Minnesota (27)
Missouri (2)
Montana (1)
Nevada (2)
New Hampshire (2)
New Jersey (191)
New York (90)
North Carolina (43)
Northern California (201)
Ohio (11)
Pennsylvania (83)
South America (13)
South Carolina (1)
Southern California (180)
Tennessee (3)
Texas (51)
United States (1439)
Utah (17)
Virginia (6)
Washington State (38)
Wisconsin (7)
10,208 Results for "166".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
July 15, 2026
·
6 min read
Press Releases
Champions Oncology Reports Revenue of $16.6 Million
March 13, 2026
·
16 min read
Press Releases
Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer
May 27, 2026
·
4 min read
Press Releases
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
June 8, 2026
·
5 min read
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 30, 2026
·
7 min read
Press Releases
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
December 18, 2025
·
5 min read
Press Releases
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
April 28, 2026
·
14 min read
Press Releases
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
April 28, 2026
·
19 min read
Press Releases
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
September 23, 2025
·
6 min read
1 of 1,021
Next
